| 1430 |
National Cancer Institute |
Html |
en |
Stomach (Gastric) Cancer Prevention (PDQ®)–Patient Version |
Smoking and H. pylori infection are important risk factors for stomach (gastric) cancer. Learn about all of the risk factors for stomach cancer and how to prevent stomach cancer in this expert-reviewed summary. |
| PDQ Screening | 0.364501 |
| cancer risk factors | 0.420087 |
| cancer treatment | 0.365273 |
| Cancer prevention | 0.532051 |
| cancer prevention trials | 0.402318 |
| healthy diet | 0.359621 |
| cancer protective factor | 0.402244 |
| United States | 0.45543 |
| prevention clinical trials | 0.399973 |
| protective factors | 0.416286 |
| antibiotics lowers | 0.358249 |
| following PDQ summaries | 0.402867 |
| Cancer Information Service | 0.393528 |
| PDQ cancer information | 0.513502 |
| number | 0.358741 |
| Clinical Trials section | 0.366407 |
| common cancer | 0.369836 |
| Prevention Editorial Board | 0.402679 |
| treatment clinical trials | 0.365364 |
| dietary supplements | 0.383267 |
| H. pylori bacteria | 0.36065 |
| National Cancer Institute | 0.462669 |
| clinical trials | 0.512934 |
|
| PDQ documents | 0.365522 |
| beta carotene | 0.388269 |
| health care | 0.357632 |
| cancer information summary | 0.455266 |
| cancer doctors | 0.360396 |
| new treatment | 0.364974 |
| breast cancer prevention | 0.387351 |
| cancer patients | 0.36264 |
| Cancer Care page | 0.385527 |
| PDQ database | 0.368612 |
| latest published information | 0.364412 |
| cancer risk factor | 0.42115 |
| NCI’s PDQ | 0.372914 |
| PDQ summary | 0.382762 |
| NCI PDQ cancer | 0.429445 |
| cancer clinical trials | 0.401358 |
| stomach cancer | 0.900678 |
| risk factors | 0.486241 |
| cancer information summaries | 0.399032 |
| comprehensive cancer information | 0.399493 |
| stomach cancer prevention | 0.492255 |
| risk | 0.486594 |
|
CLICK HERE |
| 1454 |
National Cancer Institute |
Html |
null |
Mycosis Fungoides (Including Sézary Syndrome) Treatment (PDQ®)–Health Professional Version |
Mycosis fungoides and Sézary syndrome are neoplasias of malignant T lymphocytes that affect the skin. Learn about the clinical presentation, prognosis, staging, and treatment for mycosis fungoides and Sézary syndrome in this expert-reviewed summary. |
|
|
CLICK HERE |
| 1487 |
National Cancer Institute |
Html |
en |
Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the treatment of nasopharyngeal cancer. |
| careful palpation | 0.292509 |
| definitive phase | 0.242643 |
| advanced nasopharyngeal carcinoma | 0.398201 |
| skeletal metastases | 0.266633 |
| neoadjuvant docetaxel | 0.519489 |
| pituitary gland | 0.264361 |
| chemotherapy group | 0.400142 |
| intracranial spread. | 0.264667 |
| advanced nasopharyngeal cancer. | 0.42411 |
| cranial nerves | 0.273765 |
| metastatic nodal involvement | 0.422787 |
| skull base invasion | 0.38597 |
| best possible estimate | 0.418099 |
| pathologic data | 0.276646 |
| clinical trials | 0.248887 |
| entire thyroid gland | 0.381317 |
| cisplatin | 0.267179 |
| additional information | 0.256217 |
| diagnostic imaging studies | 0.3903 |
| nasopharyngeal carcinoma | 0.426393 |
| Staging systems | 0.283956 |
| clinical staging | 0.28075 |
| tomographic scanning | 0.259213 |
| combination chemotherapy | 0.398191 |
|
| high incidence | 0.254716 |
| Clin Oncol | 0.247874 |
| fiberoptic endoscopic evaluation | 0.425036 |
| neoadjuvant arm | 0.273047 |
| 3-year overall survival | 0.371579 |
| metastatic spread | 0.269118 |
| primary tumor | 0.430532 |
| radiation treatment planning | 0.460358 |
| drug combinations | 0.39538 |
| definitive therapy | 0.394934 |
| radiologic evaluation | 0.265134 |
| Thyroid-function testing | 0.254938 |
| neoadjuvant chemotherapy | 0.942422 |
| randomized trials | 0.265028 |
| control arm | 0.346677 |
| Magnetic resonance imaging | 0.385943 |
| disease-free survival | 0.258813 |
| radiation therapy | 0.812458 |
| retropharyngeal lymph nodes | 0.399429 |
| target delineation | 0.255106 |
| nodal drainage areas | 0.414589 |
| Positron emission tomography | 0.391984 |
| standard adjuvant therapy | 0.661523 |
|
CLICK HERE |
| 1609 |
National Cancer Institute |
Html |
en |
Spirituality in Cancer Care (PDQ®)–Health Professional Version |
Expert-reviewed information summary about the influence of spirituality and religion on individuals who have cancer. Various approaches for management and intervention are discussed. |
| Illness Therapy—Spiritual Well-Being | 0.543912 |
| religious involvement | 0.499717 |
| Specific religious beliefs | 0.441508 |
| religious beliefs | 0.523457 |
| Functional Assessment | 0.445985 |
| mental health | 0.442676 |
| particular religious practices | 0.428153 |
| religious well-being score | 0.469443 |
| New York City | 0.462169 |
| spiritual needs | 0.541346 |
| overall spiritual well-being | 0.529919 |
| spiritual coping | 0.434224 |
| advanced cancer patients | 0.489002 |
| apparent spiritual distress | 0.46645 |
| religious community | 0.446225 |
| health care professionals | 0.456817 |
| greater religious involvement | 0.427553 |
| breast cancer patients | 0.460344 |
| patients | 0.767676 |
| cancer patients | 0.691703 |
| meaningful spiritual experiences | 0.440836 |
| low spiritual well-being | 0.48099 |
| acute spiritual distress | 0.458641 |
| large national survey | 0.43272 |
| spirituality | 0.547712 |
|
| quality | 0.443662 |
| lower levels | 0.487983 |
| cancer survivors | 0.4658 |
| Religious Coping Scale | 0.438267 |
| study | 0.566426 |
| religious well-being | 0.481178 |
| high levels | 0.478978 |
| life | 0.494023 |
| spiritual struggle | 0.42918 |
| spiritual well-being | 0.933157 |
| Spiritual Concerns section | 0.456015 |
| health care | 0.545672 |
| spiritual concerns | 0.673861 |
| advanced cancer | 0.607322 |
| Spiritual Well-Being Scale | 0.489529 |
| breast cancer | 0.638015 |
| spiritual care | 0.428215 |
| higher levels | 0.488544 |
| prostate cancer | 0.443702 |
| Chronic Illness Therapy—Spiritual | 0.506181 |
| positive religious coping | 0.433202 |
| religious coping methods | 0.47485 |
| cancer | 0.779595 |
| spiritual issues | 0.446953 |
|
CLICK HERE |
| 1717 |
National Cancer Institute |
Html |
en |
Prostate-Specific Antigen (PSA) Test |
A fact sheet that describes the PSA screening test for prostate cancer and explains the benefits and limitations of the test. |
| PSA test result | 0.530712 |
| standard PSA test | 0.514168 |
| prostate gland | 0.501515 |
| yearly PSA screening | 0.54489 |
| prostate cancer death | 0.513516 |
| PSA testing | 0.531895 |
| prostate portion | 0.48732 |
| PSA velocity | 0.501342 |
| prostate cancer treatment | 0.519577 |
| single PSA test | 0.516116 |
| PSA level | 0.830974 |
| PSA levels | 0.535175 |
| PSA tests | 0.519973 |
| elevated PSA measurement | 0.513617 |
| prostate health index | 0.490397 |
| age-specific psa reference | 0.520098 |
| single elevated PSA | 0.525104 |
| false-positive test result | 0.465798 |
| PSA level doubles | 0.514204 |
| prostate cancer antigen | 0.506092 |
| PSA test | 0.738071 |
| annual prostate cancer | 0.514823 |
| prostate cancers | 0.487259 |
| prostate symptoms | 0.501281 |
|
| PSA density | 0.497128 |
| prostate biopsy | 0.543132 |
| Cancer Screening Draft | 0.449679 |
| prostate cancer deaths | 0.513742 |
| PSA screening | 0.559657 |
| high-grade prostate cancer | 0.507765 |
| prostate cancer mortality | 0.517391 |
| IsoPSA. PSA | 0.495429 |
| early prostate cancer | 0.51777 |
| man | 0.497168 |
| free PSA | 0.51853 |
| benign prostate conditions | 0.512878 |
| prostate tissue | 0.490051 |
| prostate cancer screening | 0.701845 |
| prostate cancer | 0.931212 |
| elevated PSA level | 0.615668 |
| annual PSA test | 0.53093 |
| optimal PSA threshold | 0.520019 |
| prostate surgery | 0.493048 |
| versus total PSA | 0.507136 |
| et al | 0.454053 |
| Prostate biopsies | 0.493435 |
| Cancer Screening Trial | 0.453883 |
| prostate cancer recurrence | 0.511015 |
|
CLICK HERE |
| 1845 |
National Cancer Institute |
Html |
es |
Tratamiento del cáncer primario de hígado en adultos (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del cáncer primario de hígado en adultos. |
| percutaneous ethanol | 0.307629 |
| Surg Oncol Clin | 0.302767 |
| hepatocellular carcinoma based | 0.30936 |
| hepatocellular carcinoma smaller | 0.309339 |
| early hepatocellular carcinoma | 0.330465 |
| quimioembolización arterial transcatéter | 0.307969 |
| versus surgical resection | 0.303957 |
| patients with cirrhosis | 0.308968 |
| European patients with | 0.302703 |
| with hepatocellular carcinoma | 0.310631 |
| carcinoma among us | 0.306777 |
| Bruix J | 0.308485 |
| ethanol injection therapy | 0.303818 |
| carcinoma with drug | 0.307102 |
| hepatocellular carcinoma | 0.981778 |
| BCLC staging classification | 0.303901 |
| carcinoma using | 0.305993 |
| small hepatocellular carcinoma | 0.369666 |
| hepatocellular carcinoma after | 0.309033 |
| estadificación tnm | 0.30443 |
| patients with | 0.343761 |
| radiofrequency ablation | 0.30759 |
| retrospective study | 0.303001 |
| Gastroenterol Hepatol | 0.306642 |
| AASLD hepatocellular carcinoma | 0.309539 |
|
| advanced hepatocellular carcinoma | 0.325377 |
| sorafenib versus | 0.304969 |
| untreated hepatocellular carcinoma | 0.309351 |
| estadificación okuda | 0.306358 |
| Lin CC | 0.303335 |
| after percutaneous ethanol | 0.303796 |
| recurrent hepatocellular carcinoma | 0.318564 |
| estadificación bclc | 0.30882 |
| Poon RT | 0.307702 |
| controlled trial | 0.310604 |
| Cancer Staging Manual | 0.303852 |
| Radiofrequency ablation versus | 0.303706 |
| Surg Oncol | 0.303137 |
| aflatoxina b1 | 0.304027 |
| Clin Oncol | 0.306158 |
| Gastrointest Surg | 0.303366 |
| carcinoma up | 0.306683 |
| systematic review | 0.303509 |
| Llovet JM | 0.316349 |
| randomized controlled trial | 0.310237 |
| Cardiovasc Intervent Radiol | 0.302772 |
| cm hepatocellular carcinoma | 0.310978 |
| American Joint Committee | 0.305624 |
| prospective study | 0.30533 |
|
CLICK HERE |
| 2008 |
National Cancer Institute |
Html |
es |
Tratamiento de los tumores de células germinativas del sistema nervioso central infantil (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos acerca del tratamiento de los tumores de células germinativas del sistema nervioso central infantil. |
| células germinativas mixto | 0.606047 |
| radiocirugÃa estereotáctica | 0.6031 |
| siguientes procedimientos | 0.60241 |
| células madre | 0.628533 |
| efectos secundarios meses | 0.605521 |
| siguientes especialistas | 0.601341 |
| claro cuál | 0.600842 |
| siguientes tipos | 0.602105 |
| vÃa oral | 0.600964 |
| células maduras | 0.607269 |
| PDQ Descripción | 0.603561 |
| largo plazo | 0.600917 |
| efectos tardÃos | 0.61368 |
| PDQ Efectos tardÃos | 0.603681 |
| lÃquido cefalorraquÃdeo | 0.618915 |
| punción espinal.Ampliar | 0.601432 |
| National Cancer Institute | 0.601125 |
|
| sustancia llamada gadolinio | 0.602465 |
| células germinativas mixtas | 0.610091 |
| siguientes riesgos | 0.600884 |
| Instituto Nacional | 0.603777 |
| PDQ Tratamiento | 0.609778 |
| determinados cambios | 0.600765 |
| Mucha sed | 0.601358 |
| siguientes marcadores | 0.601725 |
| saco vitelino | 0.603605 |
| sistema nervioso central | 0.986252 |
| Physician Data Query | 0.603955 |
| Aboutâ„¢ Brain Tumors | 0.601381 |
| ensayos clÃnicos.Terapia | 0.602108 |
| tanta seguridad | 0.601228 |
| siguientes enlaces | 0.600982 |
| radiocirugÃa estereotáxica | 0.601123 |
|
CLICK HERE |
| 3452 |
National Cancer Institute |
Html |
es |
Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ®)–Versión para pacientes |
Resumen de información revisada por expertos sobre la preparación necesaria por parte de los proveedores de atención de la salud, los pacientes y sus familias para la transición a la atención del cáncer avanzado en la etapa final de la vida. |
| etapa final | 0.993589 |
| aspectos espirituales.Quimioterapia | 0.301674 |
| PDQ Planificar | 0.301661 |
| enfermedad progresa | 0.300844 |
| Palliative Care Organization | 0.301866 |
| Organización Nacional | 0.300803 |
| Physician Data Query | 0.304167 |
| Estados Unidos | 0.301443 |
| practique reanimación cardiorrespiratoria | 0.304362 |
| National Hospice | 0.300987 |
| sección caring connections | 0.30178 |
|
| siguientes consejos | 0.301301 |
| cuánto tiempo | 0.301394 |
| reanimación cardiorrespiratoria | 0.321909 |
| familia hará frente | 0.30286 |
| cuidados paliativos | 0.479509 |
| National Cancer Institute | 0.301056 |
| cuidado paliativo | 0.301307 |
| siguientes riesgos | 0.300668 |
| decisiones conjuntas | 0.304112 |
| Instituto Nacional | 0.301868 |
|
CLICK HERE |
| 3520 |
National Cancer Institute |
Html |
en |
Where Trials Take Place |
Information about the various settings in which cancer clinical trials take place. |
| NCI-designated cancer centers | 0.754234 |
| veterans | 0.437829 |
| clinics | 0.435881 |
| United States | 0.797764 |
| single trial | 0.604599 |
| medical centers | 0.598598 |
| offices | 0.436127 |
| Cancer.gov clinical trials | 0.786399 |
| world | 0.438646 |
| NIH Clinical Center | 0.734388 |
| clinical trials | 0.951404 |
| place | 0.614988 |
| hundreds | 0.437249 |
| NCI network trials | 0.778802 |
|
| cities | 0.438884 |
| community hospitals | 0.619062 |
| different sites | 0.602675 |
| Cancer clinical trials | 0.789309 |
| doctor | 0.455993 |
| Canada | 0.433786 |
| places | 0.435058 |
| form | 0.434135 |
| doctors | 0.439293 |
| NCI-supported clinical trials | 0.74928 |
| military hospitals | 0.617836 |
| treatment options | 0.580271 |
| towns | 0.446502 |
| form. | 0.434179 |
|
CLICK HERE |
| 16828 |
National Cancer Institute |
Html |
en |
Computational Genomics Research |
NCI’s Center for Cancer Genomics uses computational cancer genomics to derive insight about cancer genes and pathways using big data. |
| big datasets | 0.542777 |
| genomic analysis | 0.686648 |
| CCG data | 0.58375 |
| HD video | 0.465732 |
| computational approaches | 0.476443 |
| independent submitters | 0.444997 |
| Computational research | 0.470859 |
| statistical models | 0.4439 |
| analysis tools | 0.443955 |
| single cell DNA | 0.563687 |
| shares data | 0.501975 |
| large genomic datasets | 0.997114 |
| cancer driver mutations | 0.615431 |
| file cabinets | 0.459486 |
| Genomic Data Commons | 0.977931 |
| clinical datasets | 0.540686 |
| RNA expression | 0.456571 |
| multiple genomic platforms | 0.828302 |
| NCI’s Center | 0.447369 |
| exceedingly complex relationships | 0.649797 |
| Computational genomics research | 0.692909 |
| multiple modes | 0.445152 |
| cancer diagnostics | 0.487849 |
| oncogenic pathways | 0.463218 |
| computational techniques | 0.452264 |
|
| Genomics Data Analysis | 0.678168 |
| best ways | 0.449068 |
| cancer genomic data | 0.909069 |
| DNA sequence | 0.445849 |
| expert programming | 0.466152 |
| stores diverse datasets | 0.638138 |
| complex datasets | 0.550815 |
| cancer mechanisms | 0.478773 |
| scalable cloud environment | 0.595936 |
| unified view | 0.44922 |
| Genome Characterization Pipeline | 0.557584 |
| cancer researchers | 0.495463 |
| RNA sequencing | 0.45187 |
| democratize access | 0.474498 |
| Cancer Genomics Cloud | 0.816717 |
| Cancer Genome Atlas | 0.615653 |
| cancer genomic databases | 0.9082 |
| Genomics Cloud Pilots | 0.822542 |
| robust genomic data | 0.825715 |
| chromosomal copy number | 0.585632 |
| NCI Genomic Data | 0.844471 |
| exceedingly large number | 0.6264 |
| new technologies | 0.445699 |
| computationally-intensive genomic analyses | 0.756967 |
|
CLICK HERE |